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 ABSTRACT 
Pneumocystis jirovecii is a human specific, atypical fungus with a worldwide 
distribution that causes disease in immunocompromised individuals. The fungus 
proliferates in the lungs where it binds to epithelial alveolar cells, provoking severe 
pneumonia, denoted pneumocystis pneumonia (PCP). As there is no in vitro culture 
system for the organisms, and no morphological means to differentiate between P. 
jirovecii strains, we have used molecular tools to study the fungus in patient samples. 
For this purpose we have been targeting different loci in the P. jirovecii genome (ITS, 
DHPS and MSG) to address different aspects of P. jirovecii infections.  
 
The nucleotide sequence of the internal transcribed spacers (ITS) in P. jirovecii has 
been useful for isolate genotyping. We investigated the genetic diversity in Sweden by 
analyzing 408 cloned ITS sequences, from 64 clinical specimens. Several globally 
common haplotypes (combination of ITS1 and ITS2) and one local ITS2 were found. 
No correlations between certain haplotypes and patient characteristics or geographical 
associations were uncovered. In this context, a model describing the genealogic 
relationships of the strains was presented. During this process, we found that the typing 
system was generating artifactual sequences. We established a set of criteria to 
determine “bona fide” haplotypes, and optimized the typing method to avoid the 
generation of artifactual recombinants. These improved tools have enabled a more 
correct assessment of the overestimated genetic diversity of P. jirovecii populations.  
 
Trimethoprim-sulfamethoxazole (TMP-SMX) is the most widely used drug for 
prevention and treatment of PCP.  Non-synonymous substitutions in the 
dihydropteroate synthase (DHPS) gene of P. jirovecii have been found to be associated 
with sulpha exposure. It has been suggested that this is the result of the fungus 
developing resistance towards the drug. We conducted a study to investigate the 
presence of P. jirovecii DHPS mutations in the Swedish population and 104 specimens 
from patients with a suspected PCP were screened. All of the specimens (100%) 
showed a wild-type DHPS pattern, suggesting that there is no, or a very low prevalence 
of DHPS mutations in the country.  
 
One surface molecule of P. jirovecii with a probable key function in the colonization of 
the alveoli and in immune evasion is the major surface glycoprotein (MSG). The MSGs 
are encoded by the msg-gene family, and transcription is limited to a single msg-gene 
located in a unique expression site. To investigate the expressed msg-genes and the 
extent of the variability of the MSG antigen, we analyzed msg-genes located at the 
expression site.  First, we analyzed a short segment of the 5’-end of the msg-genes in 13 
patient samples. Second, we extended these studies to two full-length msg-sequences 
from two different patients. We concluded, from these analyses, that there is 
considerable variation in the potentially expressed MSG-proteins, but that a substantial 
amount of conservation can be found in the msg-gene family, even in samples of 
unrelated origins. 
 
In conclusion, the complexity of P. jirovecii populations has been overestimated but 
typing fidelity can easily be improved. The numbers of ITS haplotypes in Sweden are 
restricted, and a model depicting the relationships between strains is proposed. 
Furthermore, P. jirovecii DHPS mutations are very rare or possibly even absent in 
Sweden. Finally, the expressed msg-genes display both a remarkable variation and 
conservation. 
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1 INTRODUCTION TO THE FIELD  
 
1.1 HISTORY OF PNEUMOCYSTIS 
 
1.1.1 1909 – 1980 
 
Pneumocystis was identified for the first time in 1909 by Carlos Chagas, while he was 
studying a new disease that affected railroad workers in Brazil. Chagas identified cysts 
in the lungs of guinea pigs that had been inoculated with Trypanosoma cruzi infected 
blood. Initially, he thought what he saw was a new life form of Trypanosomes (36). He 
also found morphologically similar cyst forms in the lungs of a human case of 
trypanosomiasis (35). In 1910 Antonio Carini identified the same organisms in the 
lungs of rats infected with Trypanosoma lewisi and supported Chagas’ finding that they 
were a stage in the trypanosome life cycle (28). However, two years later, Marie and 
Pierre Delanoë at the Pasteur Institute in Paris reviewed the finding of Chagas and 
Carini and inoculated trypanosome-free rats by these kinds of cysts and could conclude, 
that they in fact, constituted a new microorganism unrelated to Trypanosomes (54). 
Delanoës named this new microorganism Pneumocystis carinii to honor Antonio 
Carini. Subsequently both Chagas and Carini retracted their first conclusions and 
provided new data that supported the research by Delanoës (8, 25, 33). In the late 1930s 
an epidemic form of interstitial plasma cell pneumonia in malnourished children was 
described in Europe (6, 18) and some years later, an association between Pneumocystis 
cysts and plasma cell pneumonia could be demonstrated, histologically, for the first 
time by van der Meer and Brug (130). Although the association had been described by 
van der Meer and Brug, three Czeck researchers Vanêk, Jírovec and Lukes are most 
credited for the first description of Pneumocystis as a causal agent of human disease  
(25). In 1952 they described the association between Pneumocystis in the lungs of 
premature and malnourished children with plasma cell pneumonia in nursing homes in 
Central and Eastern Europe (210). Pneumocystis was thereafter described as an 
important cause of epidemic pneumonia in malnourished and premature children during 
and after the Second World War. Until the 1980s, starvation and premature birth were 
the most important predisposition for Pneumocystis pneumonia (PCP) (65, 68, 166). In 
1958 Ivady and Paldy discovered that the drug pentamidine, that had previously been 
used to treat trypanosomiasis and leishmaniasis, was also useful to treat infections with 
Pneumocystis (87). The use of this drug led to decreasing mortality of PCP and the 
improvement in life quality in Europe after the war, and this treatment, led to the 
disappearance of epidemic PCP among children. In the late 1960s and early 1970, PCP 
was a rare disease with fewer than 100 cases per year in the USA. However, sporadic 
cases of PCP began to be described among immunodeficient children and 
immunosuppressed adults (84, 98, 207). Since pentamidine treatment is associated with 
high incidence of severe adverse side-effects, Hughes et al. discovered in 1975 the 
efficacy of the combined treatment of trimethoprim-sulfamethoxazole that then became 
the basis for today’s treatment and prophylaxis of PCP (85).  
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1.1.2 1981 – Today 
 
In 1981 Sandra Ford, a drug technician at the Centers for Disease Control (CDC) in 
Atlanta, USA, observed an unusual high number of requests for the drug pentamidine, 
used in the treatment of the rare disease PCP. Clinicians in the country also reported an 
increase of PCP and Kaposi’s sarcoma in previously healthy men (31, 32, 69, 125). 
This was the first evidence of the onset of the AIDS epidemic. After this point the 
number of cases exploded as PCP became one of the hallmarks of AIDS, and in 
addition to this a common complication of cancer chemotherapy and organ 
transplantations. The incidence peaked in 1990 with  20.000 cases reported to the 
CDC (11, 98). Following that, due to the widespread use of PCP prophylaxis and the 
introduction of the highly active antiretroviral therapy (HAART) in 1995 and 1996, the 
incidence started to decrease. However, PCP is still a common problem among those 
infected with HIV who either are not receiving or are not responding to HAART 
treatment, and among those who are unaware of their HIV status (21, 23, 98). In 
Europe, 2.9% of HIV infected persons have been reported to be infected with 
Pneumocystis (140). In another study, among 924 HIV infected patients who died, 56 
were caused by Pneumocystis infection (21). In a study of HIV patients in the USA 
from 1994 – 2005, 17% of hospitalizations were due to opportunistic infections and 
among these, 36% were Pneumocystis (24).  In Africa, rates between 10% – 39% of 
Pneumocystis infections have been reported among HIV infected patients with 
respiratory symptoms (1, 37, 121, 122, 209, 218, 224). Pneumocystis has also been 
reported to be the cause of pneumonia in 10% - 40% of patients without HIV (141, 
222). The increasing number of patients in the other risk groups such as transplant 
recipients, patients receiving more aggressive therapies for cancer and other conditions, 
or in patients with HIV-unrelated immune deficiencies result in an increasing number 
of individuals at risk for PCP (29, 164, 166, 222).  
 
1.1.3 Pneumocystis infection in Sweden 
 
PCP is not a notifiable disease in Sweden; there are therefore no available statistics on 
its incidence in the whole country. The Swedish Institute for Communicable Disease 
Control (SMI) in Stockholm is responsible for roughly one third to one half of all 
laboratory analyses for Pneumocystis infection in Sweden. For the last 15 years, 
approximately 50 to 100 cases have been diagnosed per year at SMI; the incidence 
peaking in 2004 with 97 cases. In addition to morphologic identification of the 
organisms in the specimens by immunofluorescence (IF) using a monoclonal antibody, 
100 to 300 specimens per year are found to be positive by polymerase chain reaction 
(PCR) (nested PCR or more recently real-time PCR). The number of PCR positive 
samples is augmenting, probably reflecting the increasing number of specimens that are 
analysed each year, rather than an increase in the actual incidence of Pneumocystis 
infection. The higher sensitivity of the PCR method also makes it possible to detect P. 
jirovecii DNA at lower concentrations including cases of subclinical colonization. The 
largest group of patients suffering from PCP during the year 2010 was patients with 
haematological malignancies (29%). Other underlying causes included 
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immunosuppression due to HIV infection (12%), inflammatory diseases (12%) and 
solid tumors (4%). During the last 15 years, HIV positivity among confirmed 
Pneumocystis infections (IF + PCR positive cases), has decreased from 50% to 6%, 
reflecting a shift in the principal cause of P. jirovecii infection.  In a retrospective study 
that identified 118 episodes of PCP in Gothenburg between 1991 and 2001, the number 
of PCP cases did not increase during the time period, and in total, 75% of the patients 
were HIV negative, a number that was 0% the first year, 33% the second year and 
increased to 83% at the last year of the study (137). In conclusion, we estimate that 
there are between 100 and 300 confirmed PCP cases per year in Sweden. This 
incidence has been stable during the last 15 years but the most common cause of 
underlying disease causing immunosuppression has shifted from HIV to 
haematological malignancies.  
 
1.2 PNEUMOCYSTIS PNEUMONIA (PCP) 
 
Pneumocystis causes a severe infection in the lungs of immunocompromised persons, 
which is characterized as an alveolar interstitial pneumonia. During infection, the 
alveolar membrane is infiltrated with leucocytes, and some observations, seem to 
indicate that this inflammation contributes more to the lung injury than the organisms 
themselves. Chest radiography usually demonstrates diffuse bilateral infiltrates, 
described as “ground glass infiltrates”. PCP typically presents with fever, fatigue, non-
productive cough and tachypnea, evolving to dyspnea and cyanosis. The symptoms 
usually progress slowly over weeks to months. However, in patients without HIV, the 
disease can have a more acute and rapid onset, developing over days, although they 
tend to harbour less organisms in the lungs than do AIDS patients (99, 161, 165). 
Diagnosis is based on identification of P. jirovecii in bronchopulmonary secretions, 
primarily induced sputum or bronchoalveolar lavage (BAL), by staining of the 
organisms or by PCR detection of their DNA (30, 58, 176).  Untreated, the infection is 
fatal due to a progressive asphyxia (suffocation). The first drug of choice for both 
treatment and prophylaxis of PCP is trimethoprim-sulfamethoxazole, given either 
intravenously or orally. One of the few alternative drugs is still pentamidine. Primary 
prophylaxis should be given to HIV infected patients with CD4+ cell counts of <200 
cells/µl. Primary prophylaxis should also be given to all solid organ transplant 
recipients during a period of at least six months. Prophylaxis is also recommended for 
high risk groups such as patients undergoing stem cell transplantation, with acute 
lymphatic leukaemia, lymphoproliferative diseases treated with T-cell suppressing 
drugs or high dose steroids, and children with primary immunodeficiency with a T-cell 
dysfunction (30, 118).  Secondary prophylaxis is given after PCP infection for six 
months, or until the underlying immunosuppression has been corrected (30, 118). 
Mortality rates for HIV patients with PCP have been reported to be 10% to 20% during 
initial infection and increase to 60% if the patient needs mechanical ventilation (45, 
164, 193). Among other patients with PCP, the mortality rates lie between 30% to 60%, 
with a greater risk among patients with cancer (164, 193). Extra-pulmonary infections 
are rare, but have been described and result from dissemination of the infection from 
the lungs to other organs (42, 190). 
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1.3 PNEUMOCYSTIS JIROVECII 
 
1.3.1 Fungus versus protozoon 
 
From the beginning it was thought that Pneumocystis was a protozoal organism, due to 
its morphological appearance and the response to the antiprotozoal drug, pentamidine. 
Today it is known that the organism is related to fungi rather than protozoa. This re-
classification was initially based on several independent findings made in the late 1980s 
and early 1990s. For example, the ribosomal RNA of Pneumocystis is more related to 
those of fungi than to protozoa (57, 183), and that mitochondrial gene sequences also 
show homology with fungal DNA (154, 201). All recent phylogenetic analyses also 
place Pneumocystis within the fungal kingdom. The Pneumocystis carinii genome 
project confirms the homology of Pneumocystis to fungi (46, 48, 49, 156). 
Pneumocystis is now classified within the phylum Ascomycota, in a unique class, order 
and family (Pneumocystidomycetes, Pneumocystidales, Pneumocystidaceae, 
respectively) with the fission yeast Schizosaccharomyces pombe as the closest relative 
(115, 192). Today, considered belonging to the kingdom of fungi, Pneumocystis 
remains an atypical fungus with several unusual features. For example, the organism is 
unable to grow in vitro in fungal culture media, it responds to antiparasitic agents and 
the cell wall contains cholesterol rather than ergosterol unlike other fungi (89), and is 
therefore resistant to the typical antifungal drug amphotericin B.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Pneumocystis jirovecii cysts recovered 
from lung alveoli stained with Toulidine Blue. Photo 
by Marianne Lebbad. 
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1.3.2 Host specificity 
 
Several different species of Pneumocystis exists. Historically it was speculated that 
Pneumocystis causing disease in humans was a zoonosis, but now it is clear that the 
fungus is host specific. A unique Pneumocystis species has been identified in about 
every mammal investigated; humans, rats, mice, rabbits, dogs, ferrets, rhesus macaques 
etc. Each of the species has diverse genetics and stringent host specificity (52, 62, 67, 
192). Earlier, all species of Pneumocystis were denoted Pneumocystis carinii and the 
different ones infecting different hosts were designated with the forma specialis (f.sp). 
For example, Pneumocystis carinii f.sp carinii was the form that infects rats, 
Pneumocystis carinii f.sp murina was the form infecting mice and Pneumocystis carinii 
f.sp hominis the form infecting humans. There has now been a name change and the 
Pneumocystis species infecting humans is denoted “Pneumocystis jirovecii”, after the 
Czech pathologist Jirovec, one of the first to describe the organism in humans (63, 
179). The form in rats (Rattus norvegicus), first described by Antonio Carini, has 
retained the name “Pneumocystis carinii”. Three more species have been formally 
described; P. wakefieldiae also infecting rats (Rattus norvegicus), P. murina in mice 
(Mus musculus) and P. oryctolagi in rabbits (Oryctolagus cuniculus) (47, 52, 93).  
 
1.3.3 Challenges 
 
Still there is no in vitro model for cultivating Pneumocystis in the laboratory, which of 
course is hampering the studies on this organism (82, 175). Currently, infected animal 
models remain the main source of organisms for laboratory studies. A complication 
with this, as described previously, is that the different species of Pneumocystis are host 
specific and not able to infect another mammal. Therefore, no animal model exists for 
P. jirovecii. The genome of P. carinii has been sequenced (156), but no genome for P. 
jirovecii is available yet. Most of the knowledge we have on the biology of 
Pneumocystis are generated in animal models. The majority of this can probably be 
extended to the biology of the human form P. jirovecii, although one has to consider 
that both phenotypic and genotypic differences exist between the different species 
described (33). To study P. jirovecii, the main source of organisms are clinical 
respiratory samples as BAL, sputum, tracheal/bronchial aspirate and in special cases, 
transbronchial and open or autopsy lung biopsies. Since the P. jirovecii organisms 
collected from these samples cannot be taken for cultivation in vitro, or in animal 
models, investigations are restricted by these circumstances.  
 
1.3.4 Genotypes 
 
No functional or morphological means for determination of phenotypic diversity of P. 
jirovecii exist. To date, investigations on the epidemiology of this pathogen rely on 
application of molecular typing techniques. Several different typing systems, at 
different loci in the P. jirovecii genome, have been described for strain characterization. 
These genetic loci include the mitochondrial large subunit rRNA (mt LSU rRNA) (200, 
202), the major surface glycoprotein (MSG) (66), cytochrome b (CYB) (204), 
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dihydropteroate synthase (DHPS) (119), dihydrofolate reductase (DHFR)(119) and the 
internal transcribed spacers (ITS) (108, 109, 116, 195). The mt LSU rRNA and ITS loci 
are frequently used because they are assumed not to be under genetic selection, and are 
therefore useful for studies on molecular evolution in circulating strains. The nucleotide 
sequence of the ITS1 and ITS2 regions, which in P. jirovecii exists as single copy 
DNA, shows the highest level of diversity and is considered to be the most 
discriminatory DNA loci for genotyping. The ITS1 region is located between the 
conserved genes encoding the 18S and 5.8S and ITS2 between 5.8S and 26S on the 
nuclear ribosomal RNA complex. These noncoding loci are spliced during rRNA 
biogenesis. Today, up to 100 different ITS haplotypes, i.e. the combination of ITS1 and 
ITS2, have been reported from 15 countries in Europe, America, Africa, Asia and 
Australia, with some globally common as well as some locally existing types (70, 79, 
109, 126, 149, 150, 159, 173, 194, 208). Infections with more than one strain at a time 
have also been shown to be quite common. The ITS types have been useful when 
investigating outbreaks, subclinical colonization and the epidemiology of PCP. 
Whether certain genotypes have an epidemiological implication is still unclear. 
Alternative typing systems using multilocus genotyping have also been described (59, 
200), and could be an alternative for P. jirovecii strain characterization. 
 
1.3.5 Life cycle  
 
There are two visible life cycle forms in the lungs of infected hosts: the trophic form 
and the cyst form with intracystical bodies. The terms “trophozoite” and “cyst” remain 
from the time when Pneumocystis was thought to be a protozoon, while the correct 
fungal nomenclature would in fact be “trophic cell” and “ascus”, respectively. Because 
of the difficulties with an in vitro system, these forms have been identified by 
morphological criteria and are found extracellular in the lungs of infected hosts. 
Trophozoites are 1-4 µm in diameter and mature cysts, 8-10 µm. During infection of 
the lung, there are more trophic forms than cysts (  10:1) (192) and most of the trophic 
forms are haploid (221). Three intermediate cyst stages have been visualized by 
electron microscopy, with 2, 4 and 8 nuclei, respectively (127, 223).  
 
 
 
 Figure 2.  Pneumocystis jirovecii cysts in a lung section stained with Toulidine Blue (A) and 
immunofluorescence (B). 
A B 
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Pneumocystis is proposed to reproduce by two life cycles (Figure 3). One life cycle 
when the throphozoites reproduce asexually by binary fission and the other one is the 
sexual cycle when two trophozoites conjugate to form the cysts and undergo meiosis 
and subsequently mitosis. As the mature cyst rupture, eight new trophozoites emanate 
from the intracystical bodies. Many genetic factors involved in meiosis and mitosis 
regulation, as well as genes or proteins potentially involved in both sexual and asexual 
replication have been identified (2, 33). Hence, Pneumocystis seems to resemble other 
ascomycotic fungi.  
 
 
 
 
 
 
 
SEXUAL ASEXUAL
Trophic form
haploid
Cystic form
diploid
Conjugation
Trophic form
haploid
Binary fission
Meiosis
Mitosis
 
 
 
Figure 3.  The proposed life cycle of Pneumocystis. 
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1.4 PNEUMOCYSTIS – HOST INTERACTIONS 
 
1.4.1 Interactions with lung cells of the host 
 
In an infected host, Pneumocystis resides in the alveoli of the lungs. The organisms 
adhere tightly to type I pneumocytes (205) and usually do not invade the host cells. 
This binding is facilitated by the interaction of fibronectin and vitronectin that bind to 
the surface of the Pneumocystis organisms and mediate the attachment to integrin 
receptors present on the pneumocytes (82, 114). The attachment of Pneumocystis 
inhibits the growth of the lung epithelial cells without destroying the cells (15, 110) and 
is thought to be required for proliferation of the trophozoites (97, 112, 193). Surface 
molecules, such as -glucan and major surface glycoprotein (MSG), in the cell wall of 
Pneumocystis appears to be important factors for the initiation of an inflammatory 
response during the infection (192). The interaction of the fungus with pneumocytes 
and alveolar macrophages initiate numerous cascades of cellular responses in both 
Pneumocystis and in the lung cells. The host immune response involves complex 
interactions between alveolar macrophages, T-lymphocytes and neutrophils.  
 
1.4.2 Immune response by the host 
 
1.4.2.1 Macrophages and innate immunity 
 
Alveolar macrophages play an important role in the clearance of the Pneumocystis 
organisms from the lungs (101, 102, 106, 111). Macrophages can bind and phagocytose 
the organisms through the interaction of the mannose receptor of the macrophage and 
the Pneumocystis major surface glycoprotein (MSG), as well as the interaction of 
macrophage dectin-1 receptor with glucans in the Pneumocystis cell wall. This uptake 
may be facilitated by IgG-opsonization. When the fungus is taken up by the 
macrophage, it is incorporated into the phagolysosome and degraded (192). These 
studies have been performed in animal models where the clearance of Pneumocystis 
was shown to be markedly impaired in macrophage-depleted rats (111). Such a 
mechanism is also likely to occur in humans infected by P. jirovecii. In addition to their 
phagocytic role, and their ability to present antigens, macrophages produce a large 
variety of proinflammatory cytokines and chemokines, such as, TNF- . TNF-  plays a 
major role in the clearance of the fungus during the infection (40, 78, 96), such as 
promoting the recruitment of neutrophils, lymphocytes and monocytes to the site of 
infection. These immune cells are crucial for the elimination of Pneumocystis, however, 
the release of oxidants, cationic proteins and proteases by these same cells can also 
damage the lung cells. Indeed, the number of recruited neutrophils has been shown to 
correlate with lung injury in humans and severity of PCP (9, 19, 113). 
 
1.4.2.2 Lymphocytes and adaptive immunity  
 
Essential for the defence against Pneumocystis are the CD4+ T-lymphocytes. They are 
recruited and activated by TNF-  and interleukin-1 (17, 20, 73, 82, 160). The risk of 
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infection in humans substantially increases with a CD4+ count of <200 cells/µl and 
treatment of HIV patients with HAART that replete the T-cells, decreases the risk of 
PCP in these individuals again. Several investigations in animal models support the fact 
that the lack of CD4+ T-cells is a prime mean by which individuals develop PCP (82). 
CD4+ T-cells coordinate the host inflammatory response by recruiting and activating 
additional immune effector cells that eliminate the Pneumocystis organisms. T-cells are 
necessary for clearance of infection but additional investigations have also shown that 
the T-cell response can also lead to significant pulmonary impairment during disease 
(16, 20, 165, 220). CD8+ T-lymphocytes may also have a role during inflammation but, 
whether or not CD8+ cells directly contribute to the defence (14, 20) or just cause lung 
injury (16, 220), is not yet clear. B-lymphocytes may also participate in the clearance of 
the fungus during infection (117). Healthy members of the general population show a 
high prevalence of serum antibodies to P. jirovecii, and some studies have shown that 
these antibody titers rise with a clinical PCP, and decrease in between two episodes of 
disease (152, 206). The role of B-cells has been proposed not only to be the production 
of antibodies, but also to regulate the CD4+ immune response by antigen presentation 
during Pneumocystis infection (117). Further studies will provide more information 
about the significance of the role played by the B-cell in the host immune response to 
this organism. An effective elimination of Pneumocystis from the lungs, without 
adverse consequences for the host, may reside in an adequate balance between pro- and 
anti-inflammatory immune responses. 
 
1.4.3 Transmission 
 
Almost all children at two years of age are already seropositive to Pneumocystis 
antigens (129, 133, 152, 153). This indicates frequent exposure to the organism. This 
primary infection is either asymptomatic or manifested as a self-limiting upper 
respiratory tract infection (105).  This high prevalence of seropositivity in children is 
one of the reasons why P. jirovecii, historically, was thought to colonize individuals 
early in life, establishing a latent infection that eventually caused PCP when the 
person’s immune system failed.  However, now both animal and human studies have 
shown that the fungus is eliminated after infection (39, 151), and the theory of 
reactivation of latent infection is no longer valid. At present, animal models and human 
studies favour an airborne transmission route for infection and PCP. Several outbreaks 
of PCP in immunosuppressed patients have been reported and molecular analyzes have 
shown nosocomial infections (7, 22, 38, 51, 76, 77, 158, 163, 172). Humans are most 
likely the reservoir and the source for transmission with an airborne person-to-person 
spread, although acquisition from environmental sources cannot be completely ruled 
out. Recent data also indicate that transplacental transmission may be possible (142). 
PCP patients are most likely not the only human source for transmission. The role of 
asymptomatic carriers and colonization is also being considered important for 
transmission of P. jirovecii.  Colonization and clearance of P. jirovecii has been 
demonstrated in humans (34), and many reports have now shown that P. jirovecii DNA 
can be detected in the respiratory tract in humans without clinical PCP.  Some groups 
of adult patients seem to be at higher risk of P. jirovecii colonization. HIV infected 
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patients are at higher risk, including those receiving PCP prophylaxis (81, 143, 157, 
200). Another high risk group is patients with chronic lung diseases (26, 144, 155, 170, 
171, 215). Smoking also increases the risk of P. jirovecii colonization and infection 
(135, 136, 143, 215). Colonization has also been shown in patients with diabetes 
mellitus, multiple myeloma, chronic lymphoid leukemia, sarcoidosis and asthma (148). 
Corticosteroid treatment and pregnancy also seem to facilitate colonization (123, 214). 
Even colonization in healthy individuals is now also under consideration. Transmission 
from PCP patients leading to P. jirovecii colonization in immunocompetent health care 
workers has also been shown (138, 213). The high seroprevalence of antibodies to P. 
jirovecii in children, and the detection of P. jirovecii DNA in healthy children, suggest 
that colonization occurs more frequently in children (212). Even the general adult 
population could potentially be a source of infection. Immunocompetent individuals 
usually clear the infection of P. jirovecii but they may transmit the organisms before 
they have fully eliminated them. The prevalence of colonization in a healthy population 
has been demonstrated to be 20% (128), although this high prevalence does not seem to 
be ubiquitous (147). In conclusion, PCP patients, patients colonized without symptoms 
of pneumonia, young children, and even healthy adults carriers are all possible sources 
of transmission of P. jirovecii. For as long as they remain infected, they may transmit 
the organisms either to other transient carriers or immunosuppressed persons at risk of 
developing PCP.  
 
1.4.4 Escape from the human immune response 
 
1.4.4.1 Antigenic variation 
 
Pneumocystis is believed to harbor a system for antigenic variation as a mean to escape 
the immune response by the host. The phenomenon of antigenic variation is the ability 
of a pathogen to systematically change the antigens that are exposed to the immune 
system of the host so that the host does not recognize it and therefore cannot eliminate 
it (53). This hypothesis fits well with the model of Pneumocystis colonization of 
healthy persons or immunocompetent patients. Individuals with a functional immune 
system will immediately mount a strong immune reaction against invading 
Pneumocystis organisms. This immune response would target antigens on the cell 
surface of the organisms and eliminate them from the lungs. Many reports, both from 
animal studies as well as from studies on P. jirovecii, indicate that Pneumocystis can 
generate antigenic variants to evade the immune response. Antigenic variation can be 
generated by different mechanisms, such as phase variation or alternate expression of 
different antigenic variants of a given surface molecule. Many organisms rely on 
switching members of a gene family to alter their appearance. These gene families 
make up the holding tank of antigenic variants that lead the immune system on “wild 
goose chase”. For example, the bacteria Borrelia hermsii and Neisseria gonorrhoeae, 
the protozoan parasites Trypanosoma brucei, Plasmodium sp., Giardia lamblia and 
Babesia bovis, as well as the fungi Candida albicans and Candida glabrata, all have 
multicopy gene families in their genome as a mechanism to vary their surface proteins 
to avoid immune recognition (3, 10, 12, 53, 61, 132, 146, 184, 189). In Pneumocystis, a 
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multicopy gene family has been identified that encodes the major surface glycoprotein 
(MSG) (66, 100, 181, 182, 186, 197). The MSG proteins are supposed to be involved in 
various biological functions including antigenic variation.   
 
1.4.4.2 Major Surface Glycoprotein (MSG) gene family 
 
In Pneumocystis, P. carinii has been the primary model for studies on antigenic 
variation, but some information regarding the other species, including P. jirovecii, is 
also available, as reviewed in (178, 180). The MSG is an important cell-surface 
molecule and most likely the key player in immune evasion and colonization of the 
host. The MSG is the most abundant protein expressed on the surface of P. jirovecii, 
with molecular masses ranging from 95-120 kDa. MSG appears to act as an attachment 
ligand to the alveolar pneumocytes and is a target of both humoral and cellular immune 
responses by the host. The msg-gene family consists of up to 100 copies located in the 
sub-telomeric regions of all chromosomes (95, 100, 180, 185, 186, 196, 197). 
Transcription is probably limited to a single msg-gene, at a given time, and the active 
copy is found in a unique expression-site located at a specific telomere-end (185). The 
expression-site contains a transcriptional promoter, the upstream conserved sequence 
(UCS) with a translational start codon, and an attached variable msg-gene. The 
expression-site, including the UCS is present only once in the genome (56, 185, 199) 
and therefore probably only one MSG protein can be expressed at any time in a single 
organism, whereas all the other members of the msg-gene family remain silent. The 
UCS encodes a putitative signal-peptide and an invariant part that is removed, en route, 
to the surface of the organism (56, 180, 199). A conserved recombination junction 
element (CRJE), present at the 3’-end of the UCS, encodes the amino acids 
MARPVKRQ, including a site putative for protease cleavage which may be the 
mechanism for how the UCS is removed from the mature antigen. This CRJE is also 
present in the 5’-end of all the silent msg-copies in the genome and may act as the 
upstream integration point for silent copies into the expression site. Recombination may 
play a role in generating further msg diversity (94, 104, 178, 198) including genetic 
exchange between different paralogous copies resulting in mosaic genes. Msg gene 
families with similar organization have been identified in P. carinii, P. murina, 
Pneumocystis from ferret and P. jirovecii (56, 71, 103, 219). The MSG gene family, 
with its restricted expression and ability to generate immense diversity, has the 
potential of being an antigenic variation system to avoid immune recognition and 
elimination by the host.  
 
1.5 DRUG RESISTANCE  
 
As mentioned before, widespread prophylaxis and treatment for P. jirovecii with sulfa-
containing drugs have effectively decreased the incidence of PCP. Trimethoprim-
sulfamethoxazole (TMP-SMX) is the most effective and widely used drug for 
prevention and treatment.  Sulfamethoxazole is considered to be the active agent 
against P. jirovecii and is a structural analogue of para-aminobenzoic acid (pABA). 
pABA is the natural substrate of the enzyme 6-hydroxymethyl-7,8-dihydropteroate 
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synthase (DHPS), an essential component of the folate synthesis pathway (174). The 
action of sulfamethoxazole is to competitively inhibit DHPS (124).  
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In P. jirovecii, two nonsynonymous point mutations
 
in the fas gene, which encodes the 
DHPS enzyme, are associated
 
with prior exposure to sulfa drugs (44, 74, 80, 91, 120, 
145, 217). These mutations, at nucleotide
 
positions 165 and 171, cause the amino acid 
substitutions Thr55Ala
 
and Pro57Ser in the DHPS protein and are assumed to lead to 
structural changes in the active site of the enzyme resulting in decreased affinity for the 
sulfa derivate and reduced inhibitory activity (Figure 5). Concerns have now been 
raised if these mutations are the result of P. jirovecii developing
 
resistance to sulfa 
drugs (177). Point mutations
 
in the DHPS-encoding genes of microorganisms such as 
Plasmodium
 
falciparum, Staphylococcus aureus, Mycobacterium leprae, and
 
Escherichia coli have been shown to confer resistance to sulfonamides (50, 72, 88, 
211). The prevalence of P. jirovecii DHPS mutations reported from
 
different countries 
ranges widely, from 0% to 81% (4, 5, 13, 43, 44, 55, 60, 64, 74, 83, 92, 107, 145, 187, 
203, 208, 216). As P. jirovecii cannot yet be cultured, conventional
 
in vitro 
susceptibility tests cannot be utilized and
 
studies of drug resistance in this organism rely 
on the use
 
of genetic markers and suitable models. Functional complementation of 
either DHPS-disrupted Escherichia coli with a mutant P. jirovecii fas gene or FOL1-
disrupted Saccharomyces cerevisiae with the fol1 gene mutated at position analogous to 
position 165 and 171 in fas results in the loss of susceptibility to sulfa (86, 131). Many 
studies are now supporting the suspicion that P. jirovecii is developing resistance to the 
drugs but the confirming evidence of DHPS mutations associated with treatment failure 
is still lacking since a number of studies have shown contradictory results and more 
studies are therefore needed (4, 74, 91). Even with some key evidences missing, many 
Figure 4.  Inhibition of folate synthesis by sulfamethoxazole and trimethoprim. 
Modified from Masters et al. (124). 
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findings are now pointing towards the fact that P. jirovecii is developing resistance to 
sulfa-containing drugs which is of major concern. 
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Figure 5.  Non-synonymous mutations at 
codon 55 and 57 in the P. jirovecii DHPS 
gene. 
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2 SCOPE OF THE THESIS  
 
When we started these studies there were many relevant questions regarding 
epidemiology, susceptibility to drugs and pathogenesis concerning P. jirovecii and PCP 
that needed and still need to be answered. There was no knowledge about the strains 
causing PCP in Sweden, and whether epidemiological relationships between episodes 
of clinical P. jirovecii infections existed in the country. Not much was either explored 
concerning the identification of genetic markers of virulence. The fact that different P. 
jirovecii genotypes exist had led to speculations that some genotypes may be more 
pathogenic or more transmissible than others. The identification of the msg-gene 
family, with its restricted expression pattern, had also introduced the theory that the 
fungus is undergoing antigenic variation as a mean to evade the host’s immune system. 
Further, evidence had been gathered suggesting that the fungus is developing resistance 
to sulfa-containing drugs, and that the resistance is associated with mutations, but 
nothing was known about how common these mutations were among strains circulating 
in Sweden. An important aspect within this field is the lack of an in vitro culture 
system, and the fact that there are no morphological means for the determination of P. 
jirovecii strains, which is impeding the studies. 
 
 
Specific aims 
 
To approach some of the above-mentioned questions different loci of the P. jirovecii 
genome was targeted. We chose three loci; the Internal Transcribed Spacers (ITS) in 
the nuclear ribosomal DNA gene complex, the Dihydropteroate Synthase (DHPS) gene 
and the Major Surface Glycoprotein (MSG) gene family with the following objectives 
to study:  
 
 
 
I. The epidemiology and genetic diversity of P. jirovecii in Sweden.  
 
II. The relevance of the ITS strain characterization system. 
 
III. The prevalence of P. jirovecii DHPS mutations in Sweden. 
 
IV. The antigenic variation of the MSG-gene family. 
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3 EXPERIMENTAL PROCEDURES 
 
Here follows a short description of the material and methods used in the studies. All 
experimental procedures are described in detail in the different papers that this thesis is 
based upon (I-IV). 
 
3.1 ETHICAL APPROVALS 
 
An ethical approval for using the specimens in these studies was obtained from the 
ethical committee of Karolinska Institutet. 
 
3.2 SPECIMENS 
 
Bronchoalveolar lavage (BAL), bronchial aspirate and sputum specimens from 
patients with suspected PCP were collected as part of routine diagnostic procedures at 
different clinical centra in Sweden between 1996 and 2003. P. jirovecii infection was 
assessed in all cases by both immunofluorescence and by PCR at the Swedish 
Institute for Communicable Disease Control (SMI) in Stockholm. The specimens 
were mixed with DTT to dissolve the samples and ethanol was added for the 
inactivation of HIV. DNA from the specimens was extracted with the purification 
system QIAamp DNA Mini Kit (QIAGEN) as part of the routine diagnostic analysis.  
 
3.3 MOLECULAR PROCEDURES 
 
3.3.1 Real-time PCR for detection of P. jirovecii 
Real-time PCR targeting the large ribosomal subunit (LSU) of P. jirovecii is 
conducted as a routine diagnostic analysis of PCP at SMI, and is described in detail in 
Paper I.  
 
3.3.2 PCR amplification  
PCRs, single or nested, of the different loci were either conducted according to an 
existing protocol previously published, or newly designed for this study. All PCRs are 
described in detail in the different Papers.  
 
3.3.3 Cloning and sequencing of PCR products  
The PCR products from the different genes (Paper I, Paper II and Paper IV) were 
cloned into the pCR
®
2.1-TOPO
®
 plasmid vector using the TOPO TA Cloning kit 
(Invitrogen). The selected bacterial colonies were screened with M13 vector-specific 
primers by PCR, described in detail in the Papers.  Recombinants were sequenced from 
both directions using M13 primers and dye terminator chemistry at the core facility of 
SMI or at Agowa GmbH, Germany. The PCR products from the full length UCS-msg 
amplification (Paper IV) were purified and cloned into the pCR
®
-XL-TOPO
®
 plasmid 
using the TOPO XL PCR Cloning Kit (Invitrogen). The selected bacterial colonies 
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were screened with a forward M13 vector-specific primer and a reverse primer 
targeting downstream the insert by PCR, described in detail in Paper IV. Colonies were 
cultured over night in LB media including kanamycin and the plasmids were purified 
with the Quantum Prep Plasmid Miniprep (Biorad). For confirmation of long inserts the 
plasmid preparations were amplified with M13 vector specific primers. Five plasmids 
from each specimen with long inserts were sequenced in both flanks by M13 primer 
and BigDye Terminator reaction to confirm the identity of the insert. One clone from 
each specimen was completely sequenced with dye terminator chemistry from both 
directions by primer walking at Agowa GmbH, Germany. 
 
3.3.4 Sequencing by pyrosequencing technology 
Pyrosequencing (Biotage), which is a sequencing-by-synthesis technique is a fast and 
accurate sequencing method for short DNA sequences and was chosen for sequencing 
of the polymorphic positions in the DHPS region (Paper III). The PCR product 
generated in the nested PCR was biotinylated at one strand and 160 bp long which is 
suitable for this method.  The PCR products were prepared for pyrosequencing 
analysing using a dedicated vacuum prep workstation (Biotage) and processed for 
sequencing analysis in a PSQ96 MA (Multi-Application) using the  PSQ96 SQA 
Reagent Kit (Biotage) as described in detail in Paper III.  
 
3.4 ANALYSES  
 
The sequence inserts obtained from the various PCRs were edited and analyzed with 
the BioEdit Sequence Alignment Editor (version 7.0.4.1). Sequence alignments were 
performed using the ClustalW software (Paper II) or the MAFFT sequence alignment 
tool (Paper IV, (90)) with default settings. Phylogenetic trees were constructed by the 
Neighbor Joining method with the MEGA3.1 (Paper II) or MEGA5 (Paper IV, (188)) 
software. In order to estimate robustness, bootstrap proportions were computed after 
1000 or 500 replications. Genealogical relationships (Paper II) were constructed with 
the TCS software (41), using the algorithm of Templeton et al. (191). Identities and 
similarities (Paper IV) were calculated with the Matrix Global Alignment Tool 
(MatGAT, (27)). Statistical analyses were performed using SigmaStat software (Paper 
I) or Stata 9.2 software (Paper II and Paper IV). Data were analysed statistically using 
the nonparametric Mann-Whitney rank sum test (Paper I and Paper IV) or the chi-
square and f-test (Paper II). p-values of 0.05 were considered significant. Diversity 
(Paper II) was calculating using the Shannon-Weiner (167) and Simpson (169) 
diversity indexes, which are dependent on richness (number of different types) and 
evenness (how many of each type). 
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4 RESULTS AND DISCUSSIONS 
 
4.1 EPIDEMIOLOGY AND GENETIC DIVERSITY OF P. JIROVECII 
 
Paper I and Paper II 
 
To study the biodiversity of P. jirovecii in Sweden 64 specimens, eight specimens per 
year, collected during the years 1996 to 2003 were chosen for the analysis. The 
specimens’ DNA were amplified with a nested PCR as described by Lee et al. (109) for 
the internal transcribed spacers (ITS), subsequently cloned and sequenced. In total 408 
sequences were analyzed and compared to already established genotypes and 
haplotypes, i.e. the combination of ITS1 and ITS2 genotypes. Overall, 41 different 
haplotypes were found in the clinical material. The result also showed that many of the 
specimens were co-infected with more than one haplotype and among these co-infected 
specimens there were sequences that we thought were recombinants. These 
recombinants were seen as rare haplotypes that appeared to be the combination of more 
common haplotypes also present in the same specimen (Figure 6). Even though a 
sexual replication cycle in Pneumocystis probably exists, that could generate 
recombinants, the high frequency of the recombinants that we saw made us consider 
that some of these recombined haplotypes maybe had been generated during the 
genotyping procedure. It is well established that recombination, or chimera formation, 
can occur during PCR when the template is a mixture of similar sequences rather than a 
single target (134, 162, 168). This led us to further investigate if the ITS typing system 
commonly used was generating artifactual recombinants.  
 
 
N 5.8S e
B 5.8S i
in vivo?
in vitro?
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B 5.8S e
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4.1.1 In vitro recombination during ITS genotyping 
 
Paper I 
 
To answer the question whether the recombinant sequences we observed were indeed 
generated in vitro we started up by mixing specimens with known haplotypes and 
typing them according to the standard protocol (109). By mixing two single infected 
Figure 6.  Recombination between two haplotypes within a specimen. 
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specimens we could show that recombinant sequences of these mixed haplotypes also 
were generated during the typing procedure. We could show that up to 37% of 
produced sequences actually were artifactual DNA sequences. We further investigate at 
what step in the genotyping protocol these artifacts were produced, and showed that the 
recombinants were mainly generated during the PCR elongation step, but that a small 
amount also could be generated later on during the cloning step. Finally, we 
investigated if it was possible to suppress the chimera formation during the typing 
procedure. We tested several modifications of the standard protocol and found that the 
number of in vitro generated recombinants could be almost abolished by using longer 
elongation time, less cycles, higher denaturation temperature and higher primer 
concentrations during the PCR. In addition to the chimera formation, the ITS region 
seems to be more prone to misincorporations compared to another gene we tested.  The 
implication of this is that artifactual haplotypes, as well as artifactual ITS1 and ITS2 
genotypes, probably have been erroneously reported as new identified strains, when 
using the ITS genotyping system. Therefore, the diversity in P .jirovecii populations 
has in all likelihood previously been overestimated. 
 
 
4.1.2 Genetic diversity of P. jirovecii isolates 
 
Paper II 
 
In the clinical material made up of the 64 respiratory specimens, 10 ITS1 and 12 ITS2 
previously established genotypes were found. In addition to these genotypes a novel 
ITS2 sequence was found and denoted “v”, according to the nomenclature put forward 
by Lee et al. (109). Among the 41 haplotypes identified, nine were found in several 
specimens each and at least once as a single infection. Haplotype Eg was the most 
frequent one followed by Ne, Bi, Eb, Ai, Ea, Ec, Jf and Iv, the latter including the novel 
ITS2v. Since 50% of the specimens were co-infected with more than one strain, and 
considering our findings with respect to the in vitro generated recombinants, we made 
efforts to exclude potential artifacts from the more complex specimens. To differentiate 
between genuine and artifactual haplotypes we set up some criteria for the definitions 
of a “bona fide” haplotype. Bona fide haplotypes were defined as haplotypes that are 
found in single infections, or those that cannot have been generated by in vitro 
recombination from other haplotypes found in the same specimen. By these criteria 
three more haplotypes (Gg, Kf and Eh) were also considered genuine haplotypes albeit 
occurring at lower frequency. In conclusion, only 12 haplotypes defined the essential 
structure of the local population of P. jirovecii organisms in Sweden (Table 1). 
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Table 1. P. jirovecii bona fide haplotypes detected in Sweden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has been suggested that certain ITS haplotypes may be associated with patient 
demographics, or be more or less virulent than others (139, 208), but no such 
correlation has been established (75, 203). In an attempt to investigate if  there was any 
association between haplotypes and other parameters we tested our material in this 
respect, but could not find any correlation between particular ITS haplotypes in co-
infection cases and we detected no differences in age, sex or underlying condition of 
the patients. We also compared frequencies of the most common haplotypes in different 
regions of Sweden covered in this work, as well as those in every year during the time 
span of this study, but no geographical, temporal or seasonal clustering of haplotypes 
was observed. However, the numbers in these calculations are relatively small so the 
absence of correlations between certain haplotypes and clinical or demographic 
correlations does not necessarily mean that the correlation is missing, and more studies 
are therefore needed. 
 
We also wanted to investigate the relationships between all major ITS types found 
worldwide, including those found in Swedish strains. In this analysis we included all 
bona fide haplotypes found in Sweden as well as sequences described in international 
studies that fulfilled our criteria of bona fide haplotypes, present at frequencies of >4%. 
The stringent inclusion criteria were chosen to be sure not to include potential 
artifactual haplotypes that could influence the results of the analysis. In total 27 
haplotypes were included and among them 11 were locally existing types from 
Thailand (Ip, Ir and Rp), Japan (Fu4, Iu3 and U1e), South Africa (Eu), Portugal (Pb), 
Australia (Isyd2), India (DEL1r) and the Swedish type Iv. At first we used classical 
phylogenetic approaches and constructed trees by Neighbor-Joining analysis with 
maximum parsimony and maximum likelihood algorithms. These trees only showed 
ITS haplotype 
Specimens (n=64) Clones (n=408) 
n % n % 
Eg 28 44 106 26 
Ne 10 16 61 15 
Bi 9 14 38 9 
Eb 9 14 44 11 
Ai 6 9 24 6 
Ea 5 8 15 4 
Ec 5 8 23 6 
Jf 5 8 24 6 
Iv (new ITS2) 4 6 17 4 
Eh 1 1.6 2 0.5 
Gg 1 1.6 3 0.7 
Kf 1 1.6 2 0.5 
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weak bootstrap values and did not provide sufficient intraspecies resolution for 
haplotype grouping. Instead we tested if coalescence theory could be used in describing 
how Pneumocystis strains are related. Coalescent theory attempts to trace all alleles of a 
gene shared by all members of a population to a single ancestral copy, the most recent 
common ancestor, still present in the population. For this purpose we used the TCS (41) 
analysis software that uses haplotype frequency and parsimony to infer relationships 
between sequences. The same haplotypes as for the phylogenetic trees were included in 
the analysis but at frequencies corresponding the rates of the different epidemiological 
studies. The coalescent analysis showed that Eg occupies a central position in the 
population and that Eg represents the most recent common ancestor, which is consistent 
with other studies (70, 159, 208). The gene genealogy did not resolve all relationships 
but showed five groups of haplotypes or clades (Figure 7). There were no apparent 
differences between Swedish types and types from other origin, which precludes the 
establishment of a geographical pattern, and is consistent with the notion that most of 
the haplotype are present worldwide.  
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Figure 7.  Genealogy of P. jirovecii ITS haplotypes. The network was derived by 
coalescent analysis using the TCS program. Lines connecting haplotypes are 
equivalent to one mutational difference. Empty nodes represent genotypes not found 
in the population. The size of ovals/square corresponds to haplotype frequency. The 
most likely recent common ancestor is depicted by a square (Eg). The introduction of 
haplotype Ee results in the relationships between types in clade II as shown in inset a. 
The types identified in Sweden are shown in gray. 
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There were two unresolved loops indicative of homoplasy or recombination in the 
network. One of the loops is introduced in the network when haplotype Ee is included 
in the analysis. Haplotype Ee is a special haplotype since it satisfies the criteria for a 
bona fide haplotype, but is the combination of the two most common haplotypes 
worldwide (Eg and Ne). In our material we hypothesize that Ee is a recombinant 
generated in vitro but that is found more frequently due to the fact that the parental 
sequences are so common. However, this variant could also be the result of 
recombination during a sexual replication. Convergence could also be anticipated to 
explain the presence of Ee since the sequences are so closely related and is a possibility 
that cannot be dismissed (Figure 8). Anyhow, Ee is a haplotype that one should keep an 
extra eye on and elucidate further whenever it is identified in a clinical material.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lastly we applied two different diversity indexes onto the material to investigate 
whether there was a difference in the diversity in Sweden compared to other countries, 
or if the diversity in Sweden had changed over time. Analysis of the Shannon-Weiner 
and Simpson Diversity indexes (167, 169), which are dependent on both richness 
(number of different types) and evenness (how many of each type), revealed no 
difference in Sweden compared to other countries.  
 
4.1.3 Summary 
 
The diversity of P. jirovecii has previously been overestimated due to the problem of 
ITS recombinants that are produced in vitro during the typing procedure. We elucidated 
this and made some changes to the standard protocol that suppresses the formation of 
these artifactual recombinants. We defined a set of criteria to discriminate genuine 
“bona fide” haplotypes from erroneous non-existing ones. In the Swedish material 
made up of 64 clinical respiratory specimens, 12 bona fide ITS haplotypes, consisting 
of 10 ITS1 and 12 ITS2 genotypes, were revealed, nine of which were common, 
recurring in several specimens. One new ITS2 sequence denoted “v” was found in four 
specimens. Half of the specimens were infected with more than one type. There were 
no associations between haplotypes and patient age, sex, underlying disease or 
Figure 8.  The relatedness of haplotypes Eg, Ne and Ee 
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geographical origin, and no differences in diversity between Sweden and other 
countries based on Shannon and Simpson index analysis. We also presented a model 
depicting the genealogic relationships of bona fide ITS haplotypes existing worldwide. 
 
 
4.2 PREVALENCE OF P. JIROVECII DHPS MUTATIONS IN SWEDEN 
 
Paper III 
 
It has been suggested that Pneumocystis can develop resistance to sulfa drugs, and that 
this resistance is due to mutations at two positions in the P. jirovecii dihydropteroate 
synthase (DHPS) gene (177). The DHPS gene including the polymorphic positions is 
located within the fas-gene that codes for several components of the folate synthesis 
pathway (124, 217). We decided to investigate whether these mutations are prevalent in 
the clinical material from Sweden. The DNA of 103 randomly chosen clinical 
respiratory specimens, collected between 1996 and 2003, were successfully amplified 
for the fas gene, and included in the study. The patients had different underlying causes 
of immunosuppression; haematological diseases (30%), HIV (17%), inflammatory 
diseases (8%), solid tumors (8%), organ transplantation (2%) and other diseases (2%). 
A part of the DHPS region in the fas gene, including the polymorphic positions 165 and 
171, was subsequently amplified and sequenced. All of the specimens (100%) showed 
a wild-type DHPS pattern. This suggests that there is no or a very low prevalence of 
DHPS mutations among P. jirovecii strains circulating in Sweden. This is a very low 
prevalence compared to other studies from different parts of the world. Only a study in 
Brazil has shown no DHPS mutations (216), but other countries have reported 
prevalence’s ranging from 4% – 81% (5, 44). It is noteworthy that in Denmark, despite 
its geographical proximity to Sweden, a prevalence as high as 20% of strains that carry 
a mutated DHPS-gene have been reported (74).  
 
P. jirovecii DHPS mutations have been associated with prior exposure to sulfa drugs in 
several studies (44, 74, 80, 91, 120, 145). Many of these studies were made exclusively 
in HIV positive patients. In our material only 17% of the patients were HIV positive, 
and it is possible that we would have found a higher frequency of mutations if the study 
had been conducted only on HIV patients. However, in Sweden there are a relatively 
low number of people living with HIV (0.06% of the Swedish population in the year 
2009). Nevertheless, none of the 19 patients diagnosed with a HIV infection in the 
study carried a strain of P. jirovecii with a mutated DHPS-gene.  
 
Extensively PCP prophylaxis or treatment with TMP-SMX alone is probably not the 
only cause leading to a high prevalence of mutant P. jirovecii strains. It has been 
postulated that a selective pressure exerted by sulfa-containing drugs to treat other 
infections than PCP contributes to the occurrence of P. jirovecii DHPS mutations (55). 
Hence, the absence of mutations in Sweden might be a result of the restricted policy of 
antibiotic management. In Sweden, TMP-SMX is not widely used to treat other 
diseases than PCP, which also is a quite rare disease, and the restricted use of this drug 
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probably contributes to the apparent absence of P. jirovecii strains carrying a mutant 
DHPS. It is also noteworthy that not all studies showing the highest prevalence of P. 
jirovecii DHPS mutations have the highest prevalence of patients on PCP prophylaxis 
(Paper III, Table 1). In fact, two studies with material from HIV patients from two 
different countries showed the same prevalence of patients being on prophylaxis (33%), 
but with DHPS mutations prevalence’s of 81% and 17%, respectively (4, 44).  
 
4.2.1 Summary  
 
The prevalence of mutant DHPS P. jirovecii strains in Sweden was very low. This low 
prevalence might be due to the low number of HIV patients in Sweden, and potentially 
the result of a restricted policy of antibiotic management.  
 
4.3 THE ANTIGENIC VARIATION OF THE MSG-GENE FAMILY 
 
Paper IV 
 
The MSG is encoded by the msg-genes, which belong to a multicopy gene-family that 
are believed to exert antigenic variation. There is only one expression locus in the 
genome, where the msg-gene that is expressed is located; probably resulting in the 
MSG protein that is exposed on the surface of the organism (180). Little is known 
about the expression and variability of this gene-family of Pneumocystis, and in 
particular P. jirovecii. This has been in part due to the inability to obtain sufficient 
quantities of undegraded RNA preparations from human-derived organisms, and the 
lack of a culture system.  We wanted to investigate the diversity of the msg-gene family 
in some of the clinical specimens. Since we were primarily interested in the expressed 
genes we designed a PCR amplification set-up targeting the msg-copy located in the 
expression site, excluding all the probably silent copies (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UCS-F1 UCS-F2 msg-R3 
msg-R1 msg3’-R1 
N120 
UCS-N120 
~ 350 bp 
UCS-msg 
~ 3000 bp 
UCS msg 
Figure 9. Schematic display of the experimental setup. The PCR allows exclusive amplification of 
the msg-genes translocated into the expression site. Horizontal arrows are depicting the primers. 
Striped boxes are showing conserved fragments downstream the Upstream Conserved Sequence 
(UCS). 
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4.3.1 N120 sequences 
 
We started by choosing 12 clinical specimens that were known to be single infections, 
as defined by ITS typing. We chose other ITS haplotypes than Eg, which is by far the 
most common one, as a mean to approach clonal infections of P. jirovecii as possible. 
In addition, a multiple infected specimen was included in the study. These 13 
specimens were amplified with a PCR generating an amplicon of  430 bp, made up by 
74 bp of the upstream conserved sequence (UCS) of the expression site and 
approximately 350 bp of the variable msg-gene. A total of 521 recombinant clones, 25 
to 52 per sample, were sequenced and analyzed. Since we were interested in the msg-
genes, we manually removed the UCS part of the sequence. The resulting 5’-region of 
the msg-gene, including the recombination junction element (CRJE), was denoted 
N120. The N120 nucleotide sequences generated from the 13 clinical specimens 
clustered into obvious groups. Within the groups there was some microvariation, up to 
5 nucleotide differences per sequence. This variation can be either due to biological 
polymorphisms or due to PCR generated errors. To simplify further analysis, sequences 
with less than 5 differences at the nucleotide level were assembled into different sets 
denoted groups (455 sequences assembled into 57 groups). From each group the most 
common sequence was chosen for further analyses, and referred to as a “type 
sequence”. The remaining 66 sequences were singletons occurring only once in a given 
specimen. In total, 123 type sequences and singletons were found in the material.  In 
almost all of the specimens more than one N120 sequence were expressed, with a 
maximum of 18 sequences (7 type sequences and 11 singletons). Only one specimen 
contained one single N120 type sequence.  
 
Interestingly, we also found out that some type sequences were present in more than 
one specimen. These sequences were denoted N120a-h. The N120a sequence was 
found in 4 different specimens (Paper IV, Figure 2). This sequence was found as two 
different variants with two single nucleotide polymorphisms (SNPs). All N120a clones 
within a specimen showed the same variant, therefore excluding the possibility that 
these sequences were generated by cross contamination of samples. These specimens 
were not related because they were collected from different patients, in different years 
and at different geographic locations. The N120b-h sequences were present in two 
specimens each. The finding of recurring sequences indicates that some N120 
sequences are more frequently expressed than others. Expressing these more frequent 
msg-genes seems also to be a common feature since 10 out of 13 samples expressed at 
least one of the N120a-h sequences. Since identical type sequences occurred in more 
than one sample, the number of non-recurring sequences after removal of the duplicates 
was 50 unique type sequences. Surprisingly, several of the type sequences also 
corresponded to sequences that have been reported previously by Kutty et al. (i.e. 
Rucl2, Rucl5, Rucl10, Rucl18, Rucl22, Rucl25, Rucl38 and Rucl41 (104)).  
 
In the material we could see what appeared to be evidence of recombination. Two 
examples of possible single cross over recombination events of N120 sequences, from 
two specimens are shown in Paper IV, Figure 6. Two more specimens showed evidence 
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of single cross-overs (data not shown), whereas another sample displayed no less than 
nine potential recombinational events (Figure 10). This multitude of recombinational 
events suggested that many of these are artifacts generated during the PCR-
amplification. However, since it is likely that hybrid genes can be generated not only in 
vitro, but also as a result of biological processes, the recombinational event in the 
N120-segment should be further investigated before they are discarded. 
 
 
                 110       120       130       140       150       160       170       180       190       200 
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
791_M    TGTAAAAATAAAATAAAAGAATATTGCGATGGACTGAAAAATGTTTCATTAACATCAGAAAAAGTACATAAAGAATTAAAAGATTTTTGCAAAGATGGAA 
791_R1   .................................................................................................... 
791_R2   .................................................................................................... 
791_R3   .................................................................................................... 
791_R4   .................................................................................................... 
791_R5   .................................................................................................... 
791_R6   ................................T...................................C.........T..................... 
791_R7   .................................................................................................... 
791_R8   ...........................................C........................................................ 
791_R9   ...........................................C........................................................ 
791_P    ................................G..........C........................................................ 
 
 
 
                 210       220       230       240       250       260       270       280       290       300 
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
791_M    ATGAAGAAAAAAAGTGCAAAGAACTAAAAACCAAAATTGGAGCAAAATGTAACACATTCAAAGATAAACTTAAAACAGCAGCTGGAAAAGACATTGTAGA 
791_R1   ...........................................................................................A...TC.A. 
791_R2   ....................................................................................T......A...TC.A. 
791_R3   .......................................A..A.........A.....T...A.CG.....G............T......A...TC.A. 
791_R4   .............A....G....................A..A.........A.....T...A.C......G............T......A...TC.A. 
791_R5   .............A....G....................A..A.........A.....T...A.C......G............T......A...TC.A. 
791_R6   .............A....G....................A..A.........A.....T...A.C......G............T......A...TC.A. 
791_R7   .............A....G....................A..A.........A.....T...A.CG.....G............T......A...TC.A. 
791_R8   ............GA....G....................A..A.........A.....T...A.C......G............T......A...TC.A. 
791_R9   .............A....G....................A..A.........A.....T...A.C......G............T.....GA...TC.A. 
791_P    .............A....G....................A..A.........A.....T.....C......G............T......A...TC.A. 
 
 
Figure 10. N120 recombinants found in one specimen. M and P refer to the parental 
sequences whereas R1 to R9 represent recombinant variants. The figure shows the 
gradual changes in difference between the parent “M” and parent “P”. 
 
 
To further analyze the diversity of the N120-segment we looked at the pairwise 
identities of the sequences. In this analysis we included all the 57 type sequences. The 
reason to include duplicate sequences, 50 unique type sequences and the recurring 
N120a-h from each sequence, was to be able to compare differences within a specimen 
as well as all the sequences in the study. The average pairwise nucleotide identity was 
69 %, ranging from 59 % to 100 %. Of the 57 nucleotide type sequences three could 
not be translated, probably PCR artifacts. The remaining 54 amino acid sequences had 
an average pairwise identity of 53 %, ranging from 37 % to 100 %, and a similarity of 
71 %, ranging from 53% to 100%. In contrast to what we speculated, there was no 
statistical difference in the average pairwise identity between sequences within a 
specimen (intra) and sequences from different specimens (inter), p >0.05. Finally we 
generated a model of the relationship between the N120-protein sequences by 
phylogenetic trees that were constructed by Neighbour-Joining analysis, but we did not 
see any particular grouping. 
 
In conclusion, there was a high degree of variability in the N120-segment with no 
apparent grouping. Several type sequences occurred more than once. Some of the 
variants showed a high degree of homology to material from another published report 
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(104). The overall variation was higher at the protein level compared to the nucleotide 
level, which is to be expected.  It was notable that the variability within a sample was as 
high as in the whole material.  
 
4.3.2 Full length msg sequences 
 
To further investigate the expressed msg-genes, we looked at two full-length genes 
located in the expression site. The same forward primers were used as for the N120-
segment but a new primer at the 3’-end on the full-length msg-gene were designed and 
used (Figure 9). This allowed us to amplify the full-length msg-gene that presumably is 
the one being expressed. We chose two specimens for this analysis, that we thought 
would be interesting, based on the N120 screening. Both specimens were single 
infections according to the ITS typing. Firstly we chose the specimen that only 
expressed one N120 type sequence. When we screened the inserts generated from the 
full-length amplification and cloning, unexpectedly several clones contained another 
sequence than the previous N120-sequence. Surprisingly, this sequence was another 
N120a sequence. We thought that this sequence was of highly interest and decided to 
sequence this one. The second specimen chosen had two different N120-sequences and 
one of them was successfully amplified, cloned and fully sequenced. Pairwise 
comparisons of these two full-length msg-sequences showed 44% identity and 66% 
similarity for the amino acids, as well as a nucleotide identity of 61%. We also 
compared these sequences with the full-length silent msg-sequences described by Kutty 
et al. (104). These 24 sequences fall into two groups “A” and “B” in the phylogenetic 
analysis (104) and our two sequences fall into one group each. We also split the 
sequences into segments of approximately 330 amino acids and made three 
independent trees. These trees showed that recombination probably had taken place 
between different msg-genes, and one potential crossover is shown in Paper IV, Figure 
5. This recombination may not represent recent events but could have occurred between 
similar segments of different genes at any time. We finally divided the msg-genes into 
different short regions, a conserved, a variable and a semi-variable, and investigated the 
variability influenced by different selective pressures. The pairwise nucleotide and 
protein identities showed that different regions are subjected to various selective 
pressures. There are both highly conserved protein regions, where the protein identity is 
higher than the nucleotide identity, and other regions with very low protein identities 
and even higher diversity at the nucleotide level.   
 
4.3.3 Summary 
 
In total, 113 partial expressed msg-genes were identified, among these 50 unique “type 
sequences” and 66 singletons. Most of the clinical single infected specimen showed 
several expressed N120-sequences at the same time. Some sequences occurred more 
frequently and some sequences were also closely related to sequences from another 
study conducted in another country. The average pairwise nucleotide identity was 69%, 
protein identity 53% and similarity 71%. Sequences generated from one specimen were 
not closer related than all the sequences in general. The overall variation was higher at 
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the protein level than the nucleotide level, indicating that there is a selective pressure to 
generate new variants of the MSG-protein. We also saw some traces of recombination 
between msg-gens, that can have occurred in the past, and recombination within the 
N120-segment, which should be further investigated. 
 
In conclusion, there is a considerable variation in the expressed msg-genes, which is 
consistent with the hypothesis that one of the functions of the msg-gene family is 
immune evasion, but at the same time there is a substantial amount of conservation.   
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5 CONCLUSIONS  
 
To investigate the atypical fungus Pneumocystis, causing PCP in humans, different loci 
of the P. jirovecii genome were analyzed. The targeted loci were ITS, DHPS and MSG 
and they were separately used to address different aspects of P. jirovecii infections 
leading to the following conclusions; 
 
 
 
■ The complexity of P. jirovecii populations has been overestimated. 
■ Typing fidelity can be improved by straightforward measures. 
■ The numbers of ITS haplotypes in Sweden are restricted. 
■ A model depicting the relationships between strains is proposed. 
■ P. jirovecii DHPS mutations are very rare or absent in Sweden. 
■ The msg-gene family displays a remarkable variation and 
conservation at the same time.  
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